Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | VDR | P11473 | 14/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18193607 | 1.00 | CDC25A (0.44) | CDC25ACDC25BCYP19A1VDRADORA3 | |
| SCHEMBL13641152 | 0.87 | CDC25A (0.51) | CDC25ACDC25BVDR | |
| SCHEMBL18193615 | 0.86 | CDC25A (0.42) | CDC25ACDC25BCYP19A1VDR | |
| SCHEMBL12213431 | 0.86 | CDC25A (0.50) | CDC25ACDC25BVDR | |
| SCHEMBL14208292 | 0.84 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDR | |
| SCHEMBL5020106 | 0.84 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDR | |
| SCHEMBL814138 | 0.84 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDR | |
| SCHEMBL817082 | 0.84 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDR | |
| SCHEMBL4787102 | 0.84 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDR | |
| SCHEMBL814645 | 0.84 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212136-B2 | Methods for producing paricalcitol | AZAD PHARMACEUTICALS INGREDIENTS AG (CH) | 2015-12-15 | — | — | US | disclosed |
| US-8754067-B2 | 22-haloacetoxy-homopregnacalciferol analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120149669-A1 | 22-Haloacetoxy-Homopregnacalciferol Analogs and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110184199-A1 | Methods For Producing Paricalcitol | AZAD PHARMA AG (CH) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149669-A1 | 22-Haloacetoxy-Homopregnacalciferol Analogs and Their Uses | CYP27B1, CYP27A1, MCL1 | CDC25A 3126/4885CDC25B 2923/4885CYP19A1 1820/4885 |
| US-20110184199-A1 | Methods For Producing Paricalcitol | CYP2R1, PTH1R, CYP24A1 | CDC25A 1705/4885CDC25B 1454/4885CYP19A1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.